ProQR Therapeutics reports earnings beat, revenue exceeds estimates

ProQR Therapeutics NV reported a first-quarter net loss of €0.03 per share on Thursday, beating the anticipated loss of €0.06 per share. Revenue for the period totaled €1.2 million, exceeding the €1.0 million estimate from analysts surveyed by Refinitiv.

The biotechnology company, focused on RNA-based therapies for inherited retinal diseases, attributed the better-than-expected results to operational efficiencies and controlled spending. Operating expenses declined year-over-year, reflecting ongoing efforts to streamline operations amid a challenging funding environment.

ProQR has faced liquidity constraints in recent quarters, with cash reserves declining as it advances its pipeline. The company has pursued strategic partnerships and cost-cutting measures to extend its financial runway while developing treatments for conditions such as Leber congenital amaurosis and Usher syndrome.

Shares of ProQR were down 2.1% in pre-market trading following the release, despite the earnings beat. The decline reflected broader biotech sector weakness and investor caution over the company’s long-term funding prospects.

Analysts noted that while the revenue beat provides a short-term positive, the sustainability of ProQR’s financial position remains a key concern. The company’s ability to secure additional funding or achieve clinical milestones will be critical in determining its trajectory in the coming quarters.